Co-variate*† | Hazard ratio | 95% CI | p value |
---|---|---|---|
*non-significant covariates excluded from model include: gender, follow up time, NIPPV use, and family history of ALS. Riluzole use was not included due to dependence on the type of clinic attended. | |||
†likelihood ratio = 42.8, df = 4, p <0.0001. | |||
General neurology clinic | 1.47 | 1.06–2.06 | 0.02 |
Bulbar onset disease | 1.41 | 1.12–1.95 | 0.02 |
Delay in diagnosis (per month) | 0.98 | 0.96–0.996 | 0.02 |
Age at diagnosis (per year) | 1.02 | 1.01–1.04 | 0.002 |